Abstract
Background: Functional imaging with 68Ga-DOTATATE PET-CT is widely employed to detect both primary and metastatic pheochromocytomas and paragangliomas (PGL), but its results may be occasionally misleading as in the case here reported.
Case Presentation: We report here a 75-year-old woman with an interaortocaval PGL that was diagnosed after a hypertensive crisis occurring during the resection of a kidney tumor. 68Ga-DOTATATE PET-CT disclosed pathologic uptake in the abdomen and at the iliac crest. After the resection of the abdominal tumor, with the histological confirmation of PGL, arterial blood pressure and metanephrine levels were normalized. Genetic testing was negative. Thereafter, the bone lesion increased in size and became painful, requiring multiple medications. A selective biopsy disclosed a metastatic lesion arising from the renal tumor.
Conclusion: The false-positive result of 68Ga-DOTATATE PET-CT is discussed.
Keywords: Paraganglioma, pheochromocytoma, imaging, Ga-DOTA-peptides, bone metastasis, differential diagnosis.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:False Positive of 68Ga-DOTATATE PET-CT in a Paraganglioma
Volume: 21 Issue: 7
Author(s): Benedetta Zampetti, Roberto Attanasio*, Marco Boniardi and Renato Cozzi
Affiliation:
- IRCCS Orthopedic Institute Galeazzi, Endocrinology Service, Milan,Italy
Keywords: Paraganglioma, pheochromocytoma, imaging, Ga-DOTA-peptides, bone metastasis, differential diagnosis.
Abstract:
Background: Functional imaging with 68Ga-DOTATATE PET-CT is widely employed to detect both primary and metastatic pheochromocytomas and paragangliomas (PGL), but its results may be occasionally misleading as in the case here reported.
Case Presentation: We report here a 75-year-old woman with an interaortocaval PGL that was diagnosed after a hypertensive crisis occurring during the resection of a kidney tumor. 68Ga-DOTATATE PET-CT disclosed pathologic uptake in the abdomen and at the iliac crest. After the resection of the abdominal tumor, with the histological confirmation of PGL, arterial blood pressure and metanephrine levels were normalized. Genetic testing was negative. Thereafter, the bone lesion increased in size and became painful, requiring multiple medications. A selective biopsy disclosed a metastatic lesion arising from the renal tumor.
Conclusion: The false-positive result of 68Ga-DOTATATE PET-CT is discussed.
Export Options
About this article
Cite this article as:
Zampetti Benedetta , Attanasio Roberto *, Boniardi Marco and Cozzi Renato, False Positive of 68Ga-DOTATATE PET-CT in a Paraganglioma, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21 (7) . https://dx.doi.org/10.2174/1871530320666200821141256
DOI https://dx.doi.org/10.2174/1871530320666200821141256 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates
Current Medicinal Chemistry ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry A Potent Inhibitor of Steroid Sulfatase (EM-1913) Blocks Tumor Growth in Nude Mice (MCF-7 Xenograft)
Current Enzyme Inhibition Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry Patented Biotechnological Applications of Serpin: an Update
Recent Patents on DNA & Gene Sequences Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ
Current Pharmaceutical Design Syntheses of 2,3-Diarylated 2H-Benzo[e][1,2]Thiazine 1,1-Dioxides and their 3,4-Dihydro Derivatives, and Assessment of their Inhibitory Activity Against MCF-7 Breast Cancer Cells
Medicinal Chemistry Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Editorial (Thematic Issue: Phytochemicals, Intracellular Signalling Pathways and Anti-Cancer Effects)
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine to Overcome Cancer Multidrug Resistance
Current Drug Metabolism New Tubulin Polymerization Inhibitor Derived from Thalidomide: Implications for Anti-Myeloma Therapy
Current Medicinal Chemistry The Urokinase Plasminogen Activator System: Role in Malignancy
Current Pharmaceutical Design The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma
Current Drug Targets Lipids as Activators of Innate Immunity in Peptide Vaccine Delivery
Current Medicinal Chemistry